The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation.

scientific article published in July 2017

The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/NDT/GFV375
P698PubMed publication ID26546592

P50authorCurie AhnQ16084618
Yu Seun KimQ59683475
Kyu Ha HuhQ60371912
Chan-Duck KimQ60393289
Jong Cheol JeongQ82369397
Wookyung ChungQ88899091
Han RoQ88899094
Joongyup LeeQ90041528
Sung Bae ParkQ90760188
Jae Berm ParkQ91304167
Seung-Yeup HanQ117266928
P2093author name stringSung Joo Kim
Sik Lee
Juhan Lee
Myoung Soo Kim
Jang-Hee Cho
Jaeseok Yang
Borae G Park
Yongjung Park
KNOW-KT Study Group
P2860cites workKNOW-KT (KoreaN cohort study for outcome in patients with kidney transplantation: a 9-year longitudinal cohort study): study rationale and methodologyQ33617623
Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patientsQ33765684
Diagnosis and prevention of chronic kidney allograft lossQ34224452
Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft RejectionQ35332030
Interferon Gamma ELISPOT Testing as a Risk-Stratifying Biomarker for Kidney Transplant Injury: Results From the CTOT-01 Multicenter StudyQ37097454
The yin and yang of B cells in graft rejection and toleranceQ37690953
Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejectionQ38123309
Pretransplant identification of acute rejection risk following kidney transplantationQ38151922
Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety.Q41527816
Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft lossQ43817587
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failureQ43918875
Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies.Q44260404
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejectionQ45259438
Identifying specific causes of kidney allograft loss.Q45810388
Complement-binding anti-HLA antibodies and kidney-allograft survivalQ46141053
Kidney allograft survival after acute rejection, the value of follow-up biopsiesQ46211382
C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodiesQ47571875
To achieve national self-sufficiency: recent progresses in deceased donation in KoreaQ47728735
Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodiesQ47789001
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.Q48005087
Antibody-mediated rejection: analyzing the risk, proposing solutions.Q50463485
A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants.Q51432032
The severity of acute cellular rejection defined by Banff classification is associated with kidney allograft outcomes.Q52876472
Clinicopathological characteristics and effect of late acute rejection on renal transplant outcomes.Q53051071
Anti-angiotensin type 1 receptor antibodies associated with antibody-mediated rejection in patients without preformed HLA-donor-specific antibody.Q53245556
Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation.Q53536001
Correlation between HLA-DRB1, HLA-DQB1 polymorphism and autoantibodies against angiotensin AT(1) receptors in Chinese patients with essential hypertension.Q54373900
P433issue7
P407language of work or nameEnglishQ1860
P921main subjectantibodyQ79460
P304page(s)1244-1250
P577publication date2017-07-01
P1433published inNephrology Dialysis TransplantationQ15710302
P1476titleThe clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation
P478volume32

Reverse relations

cites work (P2860)
Q39105369Acute antibody-mediated rejection in kidney transplant recipients
Q48295872Acute kidney transplant rejection mediated by angiotensin II type 1 receptor antibodies in a pediatric hyperimmune patient.
Q46409439Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation
Q39076219Anti-angiotensin II type 1 receptor autoantibodies (AT1R-AAs) in patients with systemic sclerosis: lack of association with disease manifestations.
Q64956036Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients.
Q37642331Endothelial Cells in Antibody-Mediated Rejection of Kidney Transplantation: Pathogenesis Mechanisms and Therapeutic Implications.
Q39268286Impact of Non-Human Leukocyte Antigen-Specific Antibodies in Kidney and Heart Transplantation
Q39217968Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection
Q42343473Renal association clinical practice guideline in post-operative care in the kidney transplant recipient
Q42233729The Presence of Anti-Angiotensin II Type-1 Receptor Antibodies Adversely Affect Kidney Graft Outcomes.
Q38877375The importance of non-HLA antibodies in transplantation

Search more.